TY - JOUR
T1 - New strategies in lung cancer
T2 - Epigenetic therapy for non-small cell lung cancer
AU - Forde, Patrick M.
AU - Brahmer, Julie R.
AU - Kelly, Ronan J.
PY - 2014/5/1
Y1 - 2014/5/1
N2 - Recent discoveries that non-small cell lung cancer (NSCLC) can be divided into molecular subtypes based on the presence or absence of driver mutations have revolutionized the treatment of many patients with advanced disease. However, despite these advances, a majority of patients are still dependent on modestly effective cytotoxic chemotherapy to provide disease control and prolonged survival. In this article, we review the current status of attempts to target the epigenome, heritable modifications of DNA, histones, and chromatin that may act to modulate gene expression independently of DNA coding alterations, in NSCLC and the potential for combinatorial and sequential treatment strategies.
AB - Recent discoveries that non-small cell lung cancer (NSCLC) can be divided into molecular subtypes based on the presence or absence of driver mutations have revolutionized the treatment of many patients with advanced disease. However, despite these advances, a majority of patients are still dependent on modestly effective cytotoxic chemotherapy to provide disease control and prolonged survival. In this article, we review the current status of attempts to target the epigenome, heritable modifications of DNA, histones, and chromatin that may act to modulate gene expression independently of DNA coding alterations, in NSCLC and the potential for combinatorial and sequential treatment strategies.
UR - http://www.scopus.com/inward/record.url?scp=84899751803&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899751803&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-13-2088
DO - 10.1158/1078-0432.CCR-13-2088
M3 - Article
C2 - 24644000
AN - SCOPUS:84899751803
SN - 1078-0432
VL - 20
SP - 2244
EP - 2248
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 9
ER -